Breast cancer surgery

Hozumi Y, Kawano M, Miyata M (1997) Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 44 745-749... 

Despite the still uncertain adverse effects profile of tibolone, it continues to be used in relieving the hot flushes caused by anti-estrogen therapy, and does so in doses that cause no additional problems. In a further double-blind, placebo-controlled study of oral tibolone 2.5 mg/day in 70 postmenopausal women taking tamoxifen after breast cancer surgery tibolone reduced the severity of hot flushes and perhaps also their incidence (3). 

We are taught in medical school, in subtle ways, that you can t trust any research findings that don t have the blessing of the temples of learning and bastions of the status quo mentioned above, even if that research was done in a respected center by a respected researcher. Look at the way they drove Dr. George Crile out of the Temple of Medicine for reporting, after years of careful research, that radical breast cancer surgery is a waste of time. His research was done at the Cleveland Clinic. Doctor Linus... 

The uses of the various anabolic steroids include management of anemia of renal insufficiency, control of metastatic breast cancer in women, and promotion of weight gain in those with weight loss after surgery, trauma, or infections. Stanozolol is used prophylactically... 

A number of potential prognostic factors have been identified for breast cancer. Prognostic factors are measurements available at diagnosis or time of surgery that in the absence of adjuvant therapy are associated with recurrence rate, death rate, or other clinical outcome. 

The goal of neoadjuvant chemotherapy in locally advanced breast cancer is cure. Complete pathologic response, determined at the time of surgery, is the desired end point. 

Tamoxifen has been widely used in the adjuvant treatment of invasive breast cancer associated to surgery and chemotherapy. It has been shown to be effective in preventing new contralateral tumors and local or peripheral recurrences (Nolvadex Adjuvant Trial Organization 1983 Cuzick and Baum 1985 Abe et al. 1998). The overview comprised 37,000 women from 55 randomized trials and included events occurring more than 5 years after randomization. The effects... 

Much research has also been conducted on everolimus and other mTOR inhibitors for use in a number of cancers. The PDA has recently approved everolimus for organ rejection prophylaxis on April 22, 2010. A Phase II trial reports it is effective in the treatment of subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis. In Oct 2010, the PDA approved its use in SEGA unsuitable for surgery. As of Oct 2010 Phase III trials are under way in breast cancer, gastric cancer, hepatocellular carcinoma, pancreatic neuroendocrine tumors (NET), and lymphoma. ... 

The management of locally advanced breast cancer requires the integration of surgery, chemotherapy, and radiation therapy. This chapter summarizes the existing experience and addresses some of the remaining issues in combined modality therapy of locally advanced and inflammatory breast cancer. 

The management of locally advanced breast cancer and inflammatory breast cancer has evolved over the past twenty years. In general, surgery has maintained a role in the combined management of this disease but most studies have tested strategies to increase the extent of pathological response, especially in view of its prognostic implications. 

Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995 13 547-552. 

---